Related Experiment Videos
Diseases of adenosine triphosphate synthesis in children
Katherine Sims1, David Holtzman
1Department of Neurology, Massachusetts General Hospital, Boston, 02129, USA.
Insights
Primary genetic oxidative-phosphorylation disorders involve complex genetic mutations affecting energy metabolism. Advances in genetic testing and imaging aid diagnosis and understanding of these multi-system diseases.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Primary genetic oxidative-phosphorylation disorders are increasingly recognized, presenting diverse clinical phenotypes.
- Initially linked to mitochondrial DNA (mtDNA) mutations, research now identifies nuclear DNA (nDNA) genes crucial for mitochondrial function.
- Numerous pathogenic mtDNA and nDNA mutations have been discovered, expanding the scope of these energy metabolism diseases.
Purpose of the Study:
- To review the expanding understanding of primary genetic oxidative-phosphorylation disorders.
- To highlight advancements in identifying genetic causes and diagnostic approaches.
- To discuss the role of new technologies in clinical assessment and research.
Main Methods:
- Review of current literature on genetic oxidative-phosphorylation disorders.
- Analysis of diagnostic methodologies, including clinical assessment, biochemical markers, enzyme assays, and genetic mutation analysis (mtDNA and nDNA).
- Inclusion of advanced physiologic imaging techniques like nuclear magnetic resonance spectroscopy and positron emission tomography.
Main Results:
- Progress in identifying both mtDNA and nDNA encoded genes critical for mitochondrial structure and function.
- Diagnosis remains challenging, requiring integrated findings from clinical presentation, biochemical data, and molecular assays.
- Physiologic imaging offers new avenues for assessing disease progression and therapeutic responses.
Conclusions:
- The understanding of genetic oxidative-phosphorylation disorders and their associated phenotypes is rapidly evolving.
- Integrated diagnostic strategies combining clinical, biochemical, and molecular approaches are essential.
- Emerging imaging technologies and ongoing biologic studies on heteroplasmy and epigenetic factors promise to enhance clinical management and research.
Abstract:
There is an expanding understanding of primary genetic oxidative-phosphorylation disorders and the recognition of new multi-system clinical phenotypes in the energy metabolism diseases. Although initially recognized in association with mitochondrial DNA mutations, there is progress in the more laborious identification of nuclear DNA encoded genes relevant to mitochondrial structure and function. More pathogenic mitochondrial DNA and nuclear DNA mutations have been identified. Diagnosis of these disorders is often difficult and relies on a concurrence of findings, including recognition of a variety of clinical signs and symptoms, biochemical marker screening, electron transport chain enzyme measurements, and mitochondrial DNA or nuclear DNA mutation assay of genes relevant to mitochondrial structure, function or adenosine triphosphate metabolic pathways. Clinical diagnostic assessment now can be augmented by physiologic imaging techniques, including nuclear magnetic resonance spectroscopy and positron emission tomography. These capabilities should be increasingly helpful for studies of clinical progression and therapeutic intervention. Biologic studies, in families and patients, are beginning to address the factors of mitochondrial replication and segregation that underlie cellular/tissue heteroplasmy and clinical variability. Most epigenetic factors affecting organ-specific and phenotypic variability, however, remain to be elaborated.